Trump says Iran war "close to over" amid hopes for more negotiations
Apellis Pharmaceuticals Inc. stock has reached a new 52-week high, touching $40.72 with a market capitalization of $5.2 billion. This milestone reflects a significant upward trajectory for the company, which has seen a remarkable 105% increase over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. The stock’s performance underscores investor confidence and interest in Apellis’ potential growth and innovation within the pharmaceuticals sector. InvestingPro Tips indicate the stock is trading near its 52-week high, though the RSI suggests it may be in overbought territory. These are just 2 of over 20 ProTips available to subscribers, along with comprehensive Pro Research Reports that transform complex data into actionable intelligence for smarter investing decisions.
In other recent news, Biogen has announced its acquisition of Apellis Pharmaceuticals for $41 per share in cash, amounting to approximately $5.6 billion in upfront equity value. The acquisition deal also includes contingent value rights that could provide Apellis shareholders with additional payments. This acquisition has prompted several analyst firms to adjust their ratings and price targets for Apellis. Roth/MKM downgraded Apellis to Neutral from Buy, while raising its price target to $41. Similarly, Mizuho maintained a Neutral rating but increased its price target from $20 to $41, reflecting the acquisition terms. Raymond James also downgraded Apellis from Outperform to Market Perform due to the acquisition agreement. Additionally, Cantor Fitzgerald downgraded the stock to Neutral from Overweight, noting the expected closure of the deal in the second quarter of 2026. These developments highlight significant shifts in analyst perspectives following the acquisition announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.